{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:34:00Z","timestamp":1763141640348,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K08658"],"award-info":[{"award-number":["19K08658"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.resinv.2021.08.002","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T01:20:39Z","timestamp":1630718439000},"page":"108-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment efficacy of LAMA versus placebo for stable chronic obstructive pulmonary disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"60","author":[{"given":"Yasuhito","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9675-9051","authenticated-orcid":false,"given":"Suguru","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1817-9761","authenticated-orcid":false,"given":"Sumito","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1794-0026","authenticated-orcid":false,"given":"Yoko","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.resinv.2021.08.002_bib1","article-title":"Tiotropium versus placebo for chronic obstructive pulmonary disease","author":"Karner","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"10.1016\/j.resinv.2021.08.002_bib2","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.resinv.2021.08.002_bib3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa1700228","article-title":"Tiotropium in early-stage chronic obstructive pulmonary disease","volume":"377","author":"Zhou","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2021.08.002_bib4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2147\/COPD.S35990","article-title":"Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit","volume":"7","author":"Ulrik","year":"2012","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"9","key":"10.1016\/j.resinv.2021.08.002_bib5","article-title":"Aclidinium bromide for stable chronic obstructive pulmonary disease","author":"Ni","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.resinv.2021.08.002_bib6","first-page":"Cd011897","article-title":"Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD)","volume":"6","author":"Ni","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.resinv.2021.08.002_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1753465814565624","article-title":"Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression","volume":"9","author":"Oba","year":"2015","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.resinv.2021.08.002_bib8","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"year":"2019","series-title":"Cochrane Handbook for systematic reviews of interventions","author":"Higgins","key":"10.1016\/j.resinv.2021.08.002_bib9"},{"key":"10.1016\/j.resinv.2021.08.002_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George's respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.resinv.2021.08.002_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/COPD-200050666","article-title":"The MCID of the transition dyspnea index is a total score of one unit","volume":"2","author":"Mahler","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.resinv.2021.08.002_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1081\/COPD-200053377","article-title":"Minimal clinically important differences in COPD lung function","volume":"2","author":"Donohue","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.resinv.2021.08.002_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.resinv.2021.08.002_bib14","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1378\/chest.118.5.1294","article-title":"The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group","volume":"118","author":"Casaburi","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.08.002_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.02.00269802","article-title":"A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease","volume":"19","author":"Casaburi","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.08.002_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1378\/chest.122.1.47","article-title":"A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol","volume":"122","author":"Donohue","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.08.002_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/thorax.58.5.399","article-title":"Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD","volume":"58","author":"Brusasco","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2021.08.002_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-143-5-200509060-00007","article-title":"Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial","volume":"143","author":"Niewoehner","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.resinv.2021.08.002_bib19","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1592\/phco.2005.25.12.1708","article-title":"Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease","volume":"25","author":"Covelli","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.resinv.2021.08.002_bib20","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.rmed.2006.03.034","article-title":"Tiotropium in COPD patients not previously receiving maintenance respiratory medications","volume":"100","author":"Adams","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2021.08.002_bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1183\/09031936.06.00062705","article-title":"The effect of tiotropium on exacerbations and airflow in patients with COPD","volume":"27","author":"Dusser","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.08.002_bib22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1159\/000089655","article-title":"The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease","volume":"73","author":"Verkindre","year":"2006","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2021.08.002_bib23","first-page":"465","article-title":"A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease","volume":"14","author":"Chan","year":"2007","journal-title":"Can Respir J"},{"key":"10.1016\/j.resinv.2021.08.002_bib24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1465-9921-8-45","article-title":"Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study","volume":"8","author":"Freeman","year":"2007","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2021.08.002_bib25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2147\/COPD.S3935","article-title":"Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance","volume":"3","author":"Ambrosino","year":"2008","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2021.08.002_bib26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3132\/pcrj.2008.00037","article-title":"Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD","volume":"17","author":"Johansson","year":"2008","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.resinv.2021.08.002_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.rmed.2007.08.003","article-title":"Improvements with tiotropium in COPD patients with concomitant asthma","volume":"102","author":"Magnussen","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2021.08.002_bib28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pupt.2007.04.003","article-title":"Tiotropium improves FEV1 in patients with COPD irrespective of smoking status","volume":"21","author":"Moita","year":"2008","journal-title":"Pulm Pharmacol Therapeut"},{"key":"10.1016\/j.resinv.2021.08.002_bib29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/COPD.S2463","article-title":"Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD","volume":"3","author":"Tonnel","year":"2008","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2021.08.002_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.rmed.2007.08.009","article-title":"A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD","volume":"102","author":"Voshaar","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2021.08.002_bib31","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(09)61298-8","article-title":"Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial","volume":"374","author":"Decramer","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2021.08.002_bib32","first-page":"197","article-title":"Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies","volume":"5","author":"Bateman","year":"2010","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2021.08.002_bib33","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1378\/chest.12-2613","article-title":"Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial","volume":"144","author":"Cooper","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2021.08.002_bib34","doi-asserted-by":"crossref","first-page":"14003","DOI":"10.1038\/npjpcrm.2014.3","article-title":"Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial","volume":"24","author":"Troosters","year":"2014","journal-title":"NPJ Primary Care Respiratory Medicine"},{"key":"10.1016\/j.resinv.2021.08.002_bib35","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1465-9921-12-156","article-title":"Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial","volume":"12","author":"D'Urzo","year":"2011","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2021.08.002_bib36","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1183\/09031936.00040712","article-title":"Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study","volume":"40","author":"Kerwin","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.08.002_bib37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1185\/03007995.2013.858618","article-title":"Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies","volume":"30","author":"D'Urzo","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.resinv.2021.08.002_bib38","first-page":"57","article-title":"Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study","volume":"10","author":"Wang","year":"2015","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2021.08.002_bib39","first-page":"1233","article-title":"Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study","volume":"11","author":"LaForce","year":"2016","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2021.08.002_bib40","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1183\/09031936.00225511","article-title":"Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study","volume":"40","author":"Jones","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.08.002_bib41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/15412555.2012.661492","article-title":"Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)","volume":"9","author":"Kerwin","year":"2012","journal-title":"COPD"},{"key":"10.1016\/j.resinv.2021.08.002_bib42","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40261-013-0138-1","article-title":"Accord COPD II: a randomized clinical\u00a0trial\u00a0to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients","volume":"33","author":"Rennard","year":"2013","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.resinv.2021.08.002_bib43","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1111\/resp.12641","article-title":"Efficacy and safety of aclidinium bromide in patients with COPD: a phase 3 randomized clinical trial in a Korean population","volume":"20","author":"Lee","year":"2015","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2021.08.002_bib44","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1001\/jama.2019.4973","article-title":"Effect of aclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease: the ASCENT-COPD randomized clinical trial","volume":"321","author":"Wise","year":"2019","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.resinv.2021.08.002_bib45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1183\/09031936.00033213","article-title":"Umeclidinium in patients with COPD: a randomised, placebo-controlled study","volume":"43","author":"Trivedi","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.08.002_bib46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2147\/COPD.S48967","article-title":"Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis","volume":"8","author":"Karabis","year":"2013","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2021.08.002_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pupt.2017.12.005","article-title":"Correlations between FEV1 and patient-reported outcomes: a pooled analy-sis of 23 clinical trials in patients with chronic obstructive pulmonary dis-ease","volume":"49","author":"Donohue","year":"2018","journal-title":"Pulm Pharmacol Therapeut"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534521001477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534521001477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:31:21Z","timestamp":1761949881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534521001477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2212534521001477"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2021.08.002","relation":{},"ISSN":["2212-5345"],"issn-type":[{"type":"print","value":"2212-5345"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment efficacy of LAMA versus placebo for stable chronic obstructive pulmonary disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2021.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}